ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022
Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Noninvasive Brain Stimulation Protects Cognitive Impairment in i.c.v. STZ-Injected Rats: Role of Adult Neurogenesis.The European journal of neuroscience · 2025Article
- Review
- Celebrating 40 years of the University of Kentucky Alzheimer's Disease Research Center.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The National Institutes of Health COVID-19 Neuro Databank/Biobank: Creation and Evolution.Neuroepidemiology · 2025Article
- Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer's-type dementia therapies.Alzheimer's research & therapy · 2024Review
- Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The role of CD47 in non-neoplastic diseases.Heliyon · 2023Review
- Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers.PharmacoEconomics · 2022Article
- Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundConsensus guidance for the development and identification of high-quality Alzheimer's disease clinical trials is needed for protocol development and conduct of clinical trials.
methodsAn ad hoc consensus committee was convened in conjunction with the Alzheimer's Association to develop consensus recommendations.
resultsConsensus was readily reached for the need to provide scientific justification, registration of trials, institutional review board oversight, conflict of interest disclosure, funding source disclosure, defined trial population, recruitment resources, definition of the intervention, specification of trial duration, appropriate payment for participant engagement, risk-benefit disclosure as part of the consent process, and the requirement to disseminate and/or publish trial results even if the study is negative.
conclusionsThis consensus guidance should prove useful for the protocol development and conduct of clinical trials, and may further provide a platform for the development of education materials that may help guide appropriate clinical trial participation decisions for potential trial participants and the general public.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.